NRx Pharmaceuticals to Post Q4 Earnings: How to Play the Stock?

NRx Pharmaceuticals NRXP is expected to report its fourth-quarter 2024 results soon. The Zacks Consensus Estimate for NRXP’s loss per share is pinned at 20 cents. In the absence of a marketed product, the company is not likely to have generated revenues in the to-be-reported quarter.

See the Zacks Earnings Calendar to stay ahead of market-making news.

In the past 60 days, the Zacks Consensus Estimate for NRx Pharmaceuticals’ 2024 loss per share has remained constant at $1.75. During the same time frame, the company’s 2025 loss per share forecast has remained constant at 8 cents.

NRXP Earnings Surprise History

NRx Pharmaceuticals’ performance has been encouraging over the trailing three quarters, with earnings beating estimates in each of the quarters. On average, NRXP registered an earnings surprise of 39.15% in the last three quarters. In the last reported quarter, the company reported an earnings surprise of 81.48%.

Earnings Whispers for NRXP

Our proven model does not conclusively predict an earnings beat for NRx Pharmaceuticals this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.

NRx Pharmaceuticals has an Earnings ESP of -0.20% and a Zacks Rank #3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Factors Shaping NRXP's Upcoming Results

In the absence of a marketed product in its commercial portfolio, the company is likely to provide a thorough update on its novel pipeline candidates, which are being developed for treating central nervous system disorders, specifically suicidal bipolar depression, chronic pain, post-traumatic stress disorder (“PTSD”) and schizophrenia.

The company has two lead drug candidates – NRX-101, an oral fixed-dose combination of D-cycloserine and lurasidone, and NRX-100, a preservative-free formulation of ketamine for intravenous (IV) infusion.

NRX-101 is being developed in a phase IIb/III study for the treatment of suicidal bipolar depression, chronic pain and PTSD, while IV ketamine (NRX-100) is being developed for the treatment of suicidal depression.

In December 2024, NRx Pharmaceuticals submitted the initial section of the new drug application (“NDA”) to the FDA for NRX-100 (IV ketamine) for the treatment of suicidal depression, which is considered a national crisis.

While assembly of the clinical data is being completed, the FDA has asked NRXP to submit the 1800-page manufacturing section (Module 3) of the NDA to enable immediate review before submitting the final efficacy data and other sections, which is expected in the first quarter of 2025.

If approved, NRX-100 would be the first medicine to treat acute suicidality in the world.

The company is expected to have provided updates regarding the clinical-stage pipeline programs on its fourth-quarter earnings call.

Research and development expenses are expected to have decreased in the to-be-reported quarter, due to the conclusion of the phase IIb/III study on NRX-101.

NRXP's Price Performance

The stock has rallied 86.1% in the past three months against the industry’s 5.4% decline. NRXP has also outperformed the S&P 500 and the sector in the same period, as seen in the chart below. NRx Pharmaceuticals is currently trading above the 200-day moving average and below the 50-day moving average.

NRXP Stock Outperforms the Industry, Sector & the S&P 500